Follow on Google News News By Tag Industry News * Plastic surgery * More Industries... News By Location Country(s) Industry News
Follow on Google News | Erchonia Europe to launch Zerona® laser at 5CCErchonia Europe, the exclusive supplier of Erchonia laser products across 28 European countries, is pleased to announce the Europe-wide launch of the Zerona® laser at this year’s 5-Continent-Congress (5CC) for Lasers and Aesthetic Medicine.
By: kdm Communications ltd Founded in 1996, Erchonia is a world leading provider of Low Level Laser Technology for medical applications, working to advance the applications of 3LT through independent research and product development with the backing of the scientific and medical communities. Unlike other laser body sculpting technologies, Zerona has been proven through double-blind clinical trials to emulsify adipose tissue without the potentially harmful effects of adipocyte cell death. Zerona’s unique mode of action leads to evacuation of fatty materials from unilocular adipocytes by inducing the formation of transitory pores within the cell membrane, emulating the body’s natural mechanism of fat depletion while reducing serum LDL and triglyceride levels. Following comprehensive evaluations, Zerona received USA FDA approval and European CE marking in 2010. Over 75,000 patients have since been treated in the US with more than a 90 % satisfaction rate, and the first units have now been installed in Europe. Visit Erchonia Europe at Booth M 15A to learn more about Erchonia’s pioneering approach and the Zerona body sculpting procedure. About Erchonia Europe Erchonia Europe, based in Oxford, is a provider of Low Level Laser Technology (3LT) for medical applications, including the potential treatment of nail fungal infections and acne, as well as complex wound management. Erchonia Europe’s Zerona® laser is a pain-free 3LT body-sculpting procedure designed to reduce fat and contour the body without invasive surgery. Zerona has been proven through double-blind clinical trials to emulsify adipose tissue and, ffollowing comprehensive evaluations, it received USA FDA approval and European CE marking in 2010. For additional information, visit www.erchoniaeurope.com For further information, contact: Jeremy Fry CEO Erchonia Europe LLP The Innovation Centre 99 Milton Park Abingdon Oxon OX14 4RY Tel: +44 (0)1235 841590 Email: enquiries@erchoniaeurope.com www.erchoniaeurope.com End
Account Email Address Disclaimer Report Abuse
|
|